EU regulator says no signs AstraZeneca vaccine led to Austria illnesses

  • World
  • Thursday, 11 Mar 2021

FILE PHOTO: A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic/File Photo

(Reuters) - The European Medicines Agency said on Wednesday there was no evidence so far linking AstraZeneca's COVID-19 vaccine to illnesses in two people who received it in Austria, one of whom died 10 days after being inoculated.

The Austrian national health authority suspended the use of a batch of the vaccine after a person who was vaccinated was diagnosed with multiple thrombosis and later died, and another was hospitalised with pulmonary embolism.

"There is currently no indication that vaccination has caused these conditions, which are not listed as side effects with this vaccine," the EMA said in its statement. (

"Although a quality defect is considered unlikely at this stage, the batch quality is being investigated."

Austria said on Sunday it was suspending inoculations with the batch as a precaution. The batch was sent to 17 EU countries in total and comprised 1 million doses of the AstraZeneca vaccine.

The Anglo-Swedish company has said all batches are subject to strict and rigorous quality controls and that there have been "no confirmed serious adverse events associated with the vaccine". It said it was in contact with Austrian authorities and would fully support the investigation.

The EU regulator said the number of thromboembolic events - marked by the formation of blood clots in the body - in people who have received the AstraZeneca vaccine is no higher than that seen in the general population, with 22 cases of such events being reported among the 3 million people who have received it as of March 9.

The EU approved AstraZeneca's shot at the end of January, saying it was effective and safe to use, while the World Health Organization listed it for emergency use in mid-February.

Adverse reactions seen in trials were short-lived for the most part and blood-clotting problems were not reported.

(Reporting by Yadarisa Shabong in Bengaluru and Keith Weir in London; Editing by Shounak Dasgupta and Paul Simao)

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 1
Cxense type: free
User access status: 3
Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!

Next In World

How human team mates got along with Lena, their new robot colleague
Australia imposes sanctions on Iran, Russia over human rights violations
New COVID-19 subvariants account for nearly 70 pct new cases in U.S.
Feature: Nicaragua keen to export coffee to China
U.S. reports over 25,000 weekly flu hospitalizations
U.S. stocks drop after hotter-than-expected PPI data
Argentina into World Cup semis on penalties after surviving Dutch fightback
Russia trying to get ballistic missiles from Iran, says Britain
Chinese books introduced to Bulgaria at book fair
'It hurts my soul': Brazil's Bolsonaro ends post-election silence

Others Also Read